Science Fair Project Encyclopedia
The Food and Drug Administration advises: "Tardive Dyskinesia, a syndrome consisting of potentially irreversible, dyskinetic movements may develop in patients treated with metoclopramide...Both the risk of developing the syndrome and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the total cumulative dose." As with any medication, you should discuss all potential benefits, potential risks, and potential side effects with your physician.
It is available under trade names such as Apo-Metoclop (Apotex), Maxeran (Hoechst Marion Roussel), Nu-Metoclopramide (Nu-Pharm), Maxolon (DermaTech), and Reglan (Weyth-Ayerst).
The contents of this article is licensed from www.wikipedia.org under the GNU Free Documentation License. Click here to see the transparent copy and copyright details